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INTRODUCTION
Sublingual immunotherapy (SLIT) has been recognized as a 
safe and effective treatment for various respiratory allergic dis-
eases.1-3 It is widely prescribed in European, South American, 
and Southeast Asian countries, including Korea4 and China. 
Safety is considered an advantage of SLIT over subcutaneous 
immunotherapy (SCIT). To date, only 11 anaphylaxis cases 
caused by SLIT have been reported.5 House dust mite (HDM)-
induced respiratory allergy is a good candidate for SLIT. Meta-
analysis showed that SLIT is more effective at treating HDM re-
spiratory allergy than hay fever.1 As the efficacy of SCIT immu-
notherapy is dose-dependent,6-8 it is quite plausible that the effi-
cacy of SLIT is also dose-dependent. In fact, several researchers 
have shown that the efficacy of SLIT administration by tablets in 
treating grass pollen allergic rhinoconjunctivitis patients is dose 
dependent.9,10 Reflecting these results, a position paper from 
The American Academy of Allergy Asthma Immunology and 
American College of Allergy Asthma Immunology,7 as well as a 
guideline from the Allergic Rhinitis and its Impact on Asthma 
(ARIA) 2008 update,11 suggested that high-dose SLIT may be ef-
fective for the treatment of respiratory allergic diseases. Howev-
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er, they do not provide any detailed information about the opti-
mal maintenance dose. Thus, the optimal maintenance dose of 
SLIT is still controversial and needs to be determined.3,7,9
The absence of consensus regarding the maintenance dose 
for SLIT has result in considerable discrepancies in the allergen 
potencies of commercially available SLIT reagents. HDM is the 
ubiquitous and most important indoor allergen in warm cli-
mate countries, and several studies have suggested that the al-
lergenic potencies of commercially available HDM SLIT re-
agents are about 10- to 20-fold different according to their man-
ufacturers.12,13 The fact that companies use their own house 
units for allergen potency makes it impossible to directly com-
pare the allergen potencies of different SLIT reagents by simply 
reviewing the manufacturers’ instruction leaflets.14,15 Accord-
ingly, knowing the allergen potencies of commercial SLIT re-
agents may be highly useful for practicing allergists. 
In this study, we compared the allergen potencies of HDM 
SLIT reagents from European and Chinese manufacturers us-
ing the ELISA inhibition test, immunoCAP inhibition tests, and 
two-site ELISA kits for measuring concentrations of the major 
HDM allergens in the SLIT reagents. 
MATERIALSAND METHODS
SLIT and SCIT reagents
In this study, 3 HDM SLIT reagents were evaluated: Staloral® 
(Stallergen, Antony, France), SLITone® (AlkAbello, Madrid, 
Spain), and Wolwopharma® (Shanghai, China). For compari-
son, SCIT reagents Dermatophagoides farinae (10,000 allergy 
unit [AU]/mL), Dermatophagoides pteronyssinus (10,000 AU/
mL), and their mixture (D. farinae 15,000 AU/mL and D. pteron-
yssinus 15,000 AU/mL) manufactured by Hollister-Stier (Spo-
kane, WA, USA) were also evaluated. The Hollister-Stier re-
agents contain 50% (v/v) glycerin or 0.4% phenol as a preserva-
tive, 0.5% sodium chloride, and 0.275% sodium bicarbonate, in 
addition to HDM. Staloral® contains sodium chloride (0.059 g), 
glycerol (0.58 g), purified water, and 300 index of reactivity (IR) 
HDM in 1 mL. SLITone® contains sodium chloride (5 mg), glyc-
erin (0.5 mL), sodium phosphate monobasic (5.95 mg), sodium 
phosphate dibasic (5.2 mg), sodium hydroxide, hydrochloric 
acid, and water in 1 mL of 1,000 standard therapeutic unit 
(STU). Wolwopharma® contains D. farinae and sodium chlo-
ride. Their allergen potencies, recommended administration 
volumes, and maintenance dosages are described in Table 1.
Two-site ELISA 
We measured group 1 and group 2 major allergens of HDM 
using two-site ELISA kits (Indoor Biotechnologies, Cardiff, UK) 
according to manufacturer’s recommendation. It can differen-
tiate the group 1 major allergens of D. pteronyssinus and. D. fa-
rinae, but it cannot differentiate the group 2 major allergen of D. 
pteronyssinus and D. farinae. The detection limits of Der p 1, 
Der f 1, and group 2 major allergens were 0.5 ng, 0.5 ng, and 0.2 
ng, respectively. 
ELISA inhibition test for specific IgE to D. pteronyssinus and D. 
farinae
For the ELISA inhibition test, pooled sera from 5 Korean aller-
gic rhinitis patients sensitized to HDM were used. First, ELISA 
plate wells were coated with 10 μg/mL of D. pteronyssinus or D. 
farinae whole-body extract (Hollister-Stier) in 50 μL of bicar-
bonate buffer (pH 9.6) overnight. Then, 50 μL of serum samples 
(1:4-diluted in 1% bovine serum albumin in phosphate buffered 
saline, pH 7.4), which were pre-incubated with various quanti-
ties of inhibitor (threefold serially diluted from 30 μg to 137.17 
ng) were added to each well and incubated for 1 hour. Subse-
quently, IgE antibodies were detected using biotinylated goat 
anti-human IgE (Vector, Burlingame, CA, USA) and streptavi-
din-peroxidase (Sigma-Aldrich, St. Louis, MO, USA). The color 
was developed with 3,3’,5,5’-tetramethylbenzidine (Kirkegaard 
and Perry Laboratories, Gaithersburg, MD, USA). The absor-
bance at 450 nm was measured after addition of 0.5 M H2SO4 to 
stop color development.
ImmunoCAP inhibition assay for D. farinae-specific IgE
For the ImmunoCAP inhibition assay, sera from 30 Korean al-
lergic rhinitis patients sensitized to HDM were used. Fifty mi-
croliters of each serum was incubated for 2 hours with various 
concentrations of inhibitors at room temperature. Each inhibi-
tor was diluted fivefold serially from 100% v/v to 0.0064% v/v 
using 1% bovine serum albumin in phosphate-buffered saline. 
IgE antibodies against D. farinae were measured using Immu-
noCAP (ThermoFischer, Uppsala, Sweden), and the percent in-
hibition was calculated. ImmunoCAP inhibition assay was re-
peated using different batches of SLIT and SCIT reagents.
RESULTS
Measurement of the concentration of protein and major 
allergens of HDM in SLIT reagents
The protein concentration in the Wolwopharma® HDM SLIT 
reagent (447.70 μg/mL) was higher than that in Staloral® (292.58 
Table 1. Allergen potencies, recommended administration volumes, and main-
tenance dosages of three commercially available SLIT reagents according to 
their manufacturers’ instruction sheets
Allergen
potency
Recommended 
administration volume
Maintenance 
dosage
Staloral® 300 IR/mL 400 µL (4 droplets) 120 IR
SLITone® 1,000 STU/mL 200 µL (vial) 200 STU
Wolwopharma® 100 µg/mL (protein
   concentration)
200 µL (4 droplets) 20 µg
IR, index of reactivity; STU, standard therapeutic unit.
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μg/mL) or SLITone® (1.71 μg/mL) (Fig. 1A). However, the con-
centrations of group 1 and group 2 major allergens of HDM were 
higher in Staloral® reagent than in SLITone® or Wolwopharma® 
(Fig. 1B). The concentration of group 1 major allergens in Stalo-
ral® HDM SLIT reagent (132.03 µg/mL) was 33- to 44.5- fold 
higher than that in SLITone® (4.00 µg/mL) or Wolwopharma® 
(2.97 µg/mL). Staloral® HDM SLIT reagent also had a higher 
concentration of group 2 major allergen than that of SLITone® or 
Wolwopharma®. The concentration of group 2 major allergen in 
Staloral® SLIT reagent (14.67 µg/mL) was 4.2-fold and 5.1-fold 
higher than in SLITone® (3.46 µg/mL) and Wolwopharma® (2.91 
µg/mL), respectively.
ELISA inhibition results
The ELISA inhibition study against HDM-specific IgE showed 
that the allergenicity of Staloral® SLIT reagent is 8.5-fold and 21-
fold higher than that of SLITone® and Wolwopharma®, respec-
tively. We also compared the allergenic potency of SLIT re-
agents with 10,000 AU Hollister-Stier SCIT HDM reagents. The 
allergenic potency of Staloral (300 IR/mL) is equal to Hollister-
Stier D. farinae SCIT (10,000 AU/mL) and 78% of Hollister-Stier 
D. pteronyssinus SCIT reagent (10,000 AU/mL) (Fig. 2A, B). In 
addition, we performed an ImmunoCAP inhibition test (Fig. 3), 
which showed results similar to the ELISA inhibition assays.
Relative potency of maintenance dose of SLIT 
The recommended volume of Staloral® is 400 μL, compared 
to 200 μL of SLITone® and Wolwopharma®. Thus, based on the 
ELISA inhibition test, the maintenance dosage of Staloral® 
HDM reagent is 17-fold higher than that of SLITone® and 42-
fold higher than that of Wolwopharma®. Based on group 1 ma-
jor allergen levels determined by two-site ELISA, the Staloral® 
HDM SLIT maintenance dose is 66.0-fold higher than SLITone® 
and 89.5-fold higher than Wolwopharma®. Group 2 major aller-
gen levels in Staloral® reagent are 8.5-fold higher than in SLI-
Tone® and 10.1-fold higher than in Wolwopharma®.
Fig. 1. Protein concentrations (A) and major allergen concentrations (B) in the house dust mite sublingual immunotherapy reagents and Hollister-Stier subcutaneous 
immunotherapy reagents. HS, Hollister-Stier; Wolwo, Wolwopharma.
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DISCUSSION
This study showed that, based on IgE binding affinity, a more 
than 42-fold difference can exist between the maintenance dos-
ages of commercially available SLIT reagents. This finding may 
be due to the lack of consensus regarding the optimal mainte-
nance dose of HDM SLIT. Our study emphasizes the practical 
importance of coming to a consensus on the appropriate main-
tenance dosage of HDM SLIT reagents. For HDM respiratory al-
lergy patients, guidelines recommend administration of 2,000 
AU for the SCIT maintenance dose.7 As the allergen potencies of 
300 IR/mL and 10,000 AU/mL are similar in this study, the daily 
maintenance dose of Staloral® is twice as high as the monthly 
maintenance dose of SCIT, suggesting that the monthly dosage 
of Staloral® is 60-fold greater than that of SCIT. We showed the 
cumulative doses of total protein and major allergens after 28 
days of treatment using 4 different products (Table 2).
Our results are consistent with those of other researchers. 
Mösges et al.12 compared the allergen potencies of Staloral® and 
SLITone® HDM SLIT reagents using the skin prick test and 
found that 1,000 STU of SLITone® is equivalent to 78 IR/mL of 
Staloral®, suggesting that the maintenance dose of Staloral® is 22 
times higher than that of SLITone®. Larenas-Linnemann et al.13 
also reported marked differences in the potencies of 4 European 
commercial HDM SLIT reagents, and showed that high-dose 
SLIT is not commonly used in Europe.
A randomized clinical study using HDM allergic asthma pa-
tients showed that high-dose SLIT (daily maintenance dose 
containing 70 μg of Der f 1) could increase the bronchial thresh-
old to allergen challenge and D. farinae-specific IgG4, but low-
dose SLIT (daily maintenance dose containing 1 μg of Der f 1) 
could not. The researchers suggested that the efficacy of SLIT in 
treating HDM allergy may also be dose-dependent, and high-
dose SLIT may be effective.16 For grass pollen allergic patients, 
the dose-response relation has been well-proven by random-
ized double-blind clinical trials using 5-grass pollen SLIT tab-
lets.9,10 However, a recent systematic review study failed to find 
a significant difference in the efficacy of SLIT using different 
maintenance dose. This is partly due to the difficulty in deter-
mining the dose of major allergens to administer,1 and partly 
because the optimal maintenance dose of HDM SLIT treat-
ment is not yet known.16 The review study may suggest that the 
therapeutic equivalence dose can vary widely. Slater et al.,17 
showed that therapeutic equivalence is achieved over a 10-fold 
range of allergen concentrations based on SCIT studies using 
dose-response data.
Previous studies reported that when the allergen concentra-
tion of SCIT is increased fourfold, adverse reactions increase 
about 5% to 10%.18 However, although local adverse reactions 
were more common using the lower dose, systemic adverse re-
actions to SLIT were not dose dependent.3 Adding immunolog-
ic adjuvants to the SLIT agents may increase the clinical effica-
cy and decrease the adverse reactions. Also, clinical efficacy can 
be sustained if the allergen capacity is low.19 
The allergen potency of an immunotherapeutic extract can be 
evaluated by 2 methods. The first is based on calculating the 
concentration of major allergens using two-site ELISA or the ra-
dial immunodiffusion method. Another method involves com-
paring total allergen potency, usually by an ELISA inhibition 
test or an in vivo skin test.20,21 In this study, we found an up to 
42.5-fold difference in total allergen potency but a smaller dif-
ference (up to 17.4-fold) in the concentration of group 1 major 
allergens of HDM between reagents. This result is consistent 
with other reports that have shown marked discrepancies in 
the major allergen concentrations in extracts even when they 
had equal allergen potency.13,20 For measurements of group 1 
and 2 major allergens, we used a two-site ELISA kit from Indoor 
Biotechnologies using monoclonal antibodies. Monoclonal an-
tibodies are usually specific and cannot detect all isoallergens 
of a major allergen,22 and this method has not yet been validat-
ed for standardization of allergen extracts.23 Thus, the measure-
ment may be different when using another two-site ELISA kit, 
and this might represent a limitation of our study. This issue 
was unambiguously recognized by the CREATE (Certified Ref-
erences for Allergens and Test Evaluation) consortium.23,24 They 
Table 2. Cumulative doses of total protein and major allergens after 28-day 
treatment using 4 different products
Total protein (μg) Der p 1 (μg) Der f 1 (μg) Der 2 (μg)
Staloral® 3,276.90 1,169.28 309.12 164.64
SLITone® 9.58 19.04 3.36 19.60
Wolwopharma® 2,507.12 14.00 2.80 16.24
Hollister-Stier® 879.70 54.86 2.72 13.28
Fig. 3. ImmunoCAP inhibition of D. farinae–specific IgE with house dust mite 
sublingual immunotherapy reagents and Hollister-Stier subcutaneous immuno-
therapy reagents. HS, Hollister-Stier; Wolwo, Wolwopharma (D. farinae 15,000 
AU/mL and D. pteronyssinus 15,000 AU/mL mixture).
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have since tried to develop acceptable recombinant major al-
lergens, as well as two-site ELISA kits for each major allergen, to 
be used as international standard materials. In this context, the 
European Pharmacopoeia Commission has recently adopted 
only 2 recombinant allergens as Chemical Reference Substanc-
es. They are currently used as reference standards for the deter-
mination of Bet v 1 and Phl p 5 concentrations by ELISA. How-
ever, guidelines for SCIT recommend 5-20 μg for the mainte-
nance dose, emphasizing the importance of the concentration 
of major allergens.25 We are not sure yet whether major allergen 
concentration or total allergen potency is more important in the 
efficacy of immunotherapy. Our study also found that allergen 
potencies of SLIT reagents are not correlated with protein con-
tent. The protein concentration of Staloral® was 292.58 μg/mL, 
and the concentration of group 1 major allergens was responsi-
ble for 45.1% (132.08 μg/mL) of whole protein concentration, 
indicating the high quality of raw material used for manufactur-
ing this SLIT reagent.
Our results reveal marked differences in the allergen poten-
cies of different SLIT reagents. However, as we did not study 
their clinical efficacy, our results should not be taken as an indi-
cation of their clinical efficacy. Our data strongly suggest that 
further dose response studies to determine the clinical effica-
cies and maintenance dosages of HDM SLIT reagents studies 
are urgent. Our results also showed that high-dose SLIT is not 
yet in common use for HDM respiratory allergy patients who 
have been treated with SLIT. 
ACKNOWLEDGMENTS
This study was supported by a grant of the Korean Healthcare 
Technology R&D project, Ministry of Health and Welfare, Re-
public of Korea (A092076).
REFERENCES
1. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews 
of sublingual immunotherapy (SLIT). Allergy 2011;66:740-52.
2. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy 
of sublingual immunotherapy for house dust mites respiratory al-
lergy: results of a GA2LEN meta-analysis. Allergy 2009;64:1570-9.
3. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani 
CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy 
Organization Position Paper 2009. Allergy 2009;64 Suppl 91:1-59.
4. Hur GY, Kim TB, Han MY, Nahm DH, Park JW; Allergen and Im-
munotherapy Work Group of the Korean Academy of Asthma, Al-
lergy and Clinical Immunology (KAAACI). A survey of the pre-
scription patterns of allergen immunotherapy in Korea. Allergy 
Asthma Immunol Res 2013;5:277-82.
5. Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, De-
moly P. Sublingual allergen immunotherapy: mode of action and 
its relationship with the safety profile. Allergy 2012;67:302-11.
6. Norman PS. An overview of immunotherapy: implications for the 
future. J Allergy Clin Immunol 1980;65:87-96.
7. Joint Task Force on Practice Parameters; American Academy of Al-
lergy, Asthma and Immunology; American College of Allergy, 
Asthma and Immunology; Joint Council of Allergy, Asthma and 
Immunology. Allergen immunotherapy: a practice parameter sec-
ond update. J Allergy Clin Immunol 2007;120:S25-85.
8. Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nel-
son HS. A double-blind, placebo-controlled immunotherapy dose-
response study with standardized cat extract. J Allergy Clin Immu-
nol 2003;111:155-61.
9. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublin-
gual immunotherapy with once-daily grass allergen tablets: a ran-
domized controlled trial in seasonal allergic rhinoconjunctivitis. J 
Allergy Clin Immunol 2006;117:802-9.
10. Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, et al. 
Optimal dose, efficacy, and safety of once-daily sublingual immu-
notherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. 
J Allergy Clin Immunol 2007;120:1338-45.
11. Bousquet J, Bieber T, Fokkens W, Humbert M, Kowalski ML, Nigge-
mann B, et al. Consensus statements, evidence-based medicine 
and guidelines in allergic diseases. Allergy 2008;63:1-4.
12. Mösges R, Pasch N, Schlierenkämper U, Lehmacher W. Compari-
son of the biological activity of the most common sublingual aller-
gen solutions made by two European manufacturers. Int Arch Al-
lergy Immunol 2006;139:325-9.
13. Larenas-Linnemann D, Esch R, Plunkett G, Brown S, Maddox D, 
Barnes C, et al. Maintenance dosing for sublingual immunothera-
py by prominent European allergen manufacturers expressed in 
bioequivalent allergy units. Ann Allergy Asthma Immunol 
2011;107:448-58.e3.
14. Cox L, Jacobsen L. Comparison of allergen immunotherapy prac-
tice patterns in the United States and Europe. Ann Allergy Asthma 
Immunol 2009;103:451-59.
15. Larenas-Linnemann D, Cox LS; Immunotherapy and Allergy Diag-
nostics Committee of the American Academy of Allergy, Asthma 
and Immunology. European allergen extract units and potency: re-
view of available information. Ann Allergy Asthma Immunol 2008; 
100:137-45.
16. Bush RK, Swenson C, Fahlberg B, Evans MD, Esch R, Morris M, et 
al. House dust mite sublingual immunotherapy: results of a US tri-
al. J Allergy Clin Immunol 2011;127:974-81.e1-7.
17. Slater JE, Pastor RW. The determination of equivalent doses of 
standardized allergen vaccines. J Allergy Clin Immunol 2000; 
105:468-74.
18. Cox L, Esch RE, Corbett M, Hankin C, Nelson M, Plunkett G. Aller-
gen immunotherapy practice in the United States: guidelines, 
measures, and outcomes. Ann Allergy Asthma Immunol 2011;107: 
289-99.
19. Francis JN, Durham SR. Adjuvants for allergen immunotherapy: 
experimental results and clinical perspectives. Curr Opin Allergy 
Clin Immunol 2004;4:543-8.
20. van Ree R. Indoor allergens: relevance of major allergen measure-
ments and standardization. J Allergy Clin Immunol 2007;119:270-7.
21. Jeong KY, Hong CS, Lee JS, Park JW. Optimization of allergen stan-
dardization. Yonsei Med J 2011;52:393-400.
22. Park JW, Kim KS, Jin HS, Kim CW, Kang DB, Choi SY, et al. Der p 2 
isoallergens have different allergenicity, and quantification with 
2-site ELISA using monoclonal antibodies is influenced by the iso-
allergens. Clin Exp Allergy 2002;32:1042-7.
23. van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O, 
Potency of Mite Sublingual Immunotherapy Reagents
Allergy Asthma Immunol Res. 2015 March;7(2):124-129. http://dx.doi.org/10.4168/aair.2015.7.2.124
AAIR
http://e-aair.org  129
et al. The CREATE project: development of certified reference mate-
rials for allergenic products and validation of methods for their 
quantification. Allergy 2008;63:310-26.
24. Chapman MD, Ferreira F, Villalba M, Cromwell O, Bryan D, Becker 
WM, et al. The European Union CREATE project: a model for in-
ternational standardization of allergy diagnostics and vaccines. J 
Allergy Clin Immunol 2008;122:882-9.e2.
25. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: thera-
peutic vaccines for allergic diseases. A WHO position paper. J Aller-
gy Clin Immunol 1998;102:558-62.
